Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
Source: Motley Fool
2026-02-16 01:55:14 ET
On Feb. 2, 2026, Harold Bernstein, President, R&D & CMO of Maze Therapeutics (NASDAQ:MAZE) , exercised 15,000 options and immediately sold the resulting shares in an open-market transaction, fully divesting his direct ownership, according to a SEC Form 4 filing .
Transaction value based on SEC Form 4 weighted average purchase price ($46.02).
Maze Therapeutics Inc.
NASDAQ: MAZE
MAZE Trading
-0.79% G/L:
$44.57 Last:
137,180 Volume:
$44.62 Open:
MAZE Latest News
February 25, 2026 07:00:00 am
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 18, 2026 03:50:42 pm
Marc Andreessen's a16z Invests $465 Million in Navan's Corporate Spending Platform, According to Recent SEC Filing
February 16, 2026 01:55:14 am
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
February 04, 2026 07:00:00 am
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
MAZE Stock Data
$2,327,537,506
23,771,005
0.82%
31
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
